Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 118 of 6351
-
Can a new immune drug outsmart Hard-to-Treat tumors?
Disease control Recruiting nowThis is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent and in combination with chemotherapy administered intravenously in participants with advanced solid tumors that are antigen-rich.
Phase 1/2 • Sponsor: Marengo Therapeutics, Inc. • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Super-Sized semaglutide: could a 7.2 mg dose be a Game-Changer for obesity and diabetes?
Disease control CompletedThis study will look at how much weight participants will lose and how much blood sugar control they achieve from the start to the end of the study. The weight loss in participants taking the investigational high dose of semaglutide will be compared to the weight loss in people t…
Phase 3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Sound waves may help chemo reach deadly childhood brain tumors
Disease control OngoingThe purpose of this study is to evaluate the safety and efficacy of targeted blood brain barrier disruption with Exablate Model 4000 Type2.0/2.1 in combination with Doxorubicin therapy for the treatment of DIPG in pediatric patients
Phase 1/2 • Sponsor: InSightec • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New High-Dose semaglutide shows major weight loss in obesity trial
Disease control CompletedThis study will look at how much weight participants will lose from the start to the end of the study. The weight loss in participants taking the investigational high dose of semaglutide will be compared to the weight loss in people taking "dummy" medicine and a lower dose of sem…
Phase 3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Stroke drug aims to boost brain recovery after clot removal
Disease control CompletedEmergent reperfusion is the main goal for acute ischemic stroke therapy (AIS). Endovascular therapy (EVT) is recommended within 6 hrs of stroke onset, and up to 24 hrs following perfusion imaging criteria. Despite the major benefit associated with MT, more than 50% of the patien…
Phase 2/3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Can a Choice-Based HIV prevention model with Long-Acting shots cut infections in east africa?
Prevention CompletedThe overall purpose of this SEARCH CAB-LA (Cabotegravir Injectable Suspension) randomized extension study is to determine if adding the option of CAB-LA as a prevention choice using a person-centered dynamic choice HIV (human immunodeficiency virus) prevention model, with option …
Phase 4 • Sponsor: University of California, San Francisco • Aim: Prevention
Last updated Aug 28, 2026 00:00 UTC
-
Can a drug combo outperform standard therapy for a rare kidney cancer?
Disease control OngoingThis is a multicenter, randomized (2:1), open-label, controlled Phase 3 trial of XL092 in combination with nivolumab versus sunitinib in subjects with unresectable, locally advanced or metastatic nccRCC who have not received prior systemic anticancer therapy.
Phase 3 • Sponsor: Exelixis • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Triple therapy shows promise for intermediate liver cancer
Disease control CompletedThe purpose of this study is to evaluate the safety and efficacy of transarterial chemoembolization (TACE) in combination with PD-1/PD-L1 Inhibitors and molecular target therapies in patients with Intermediate-stage hepatocellular carcinoma (HCC).
Sponsor: Zhongda Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New Dual-Target CAR T-Cell therapy aims to beat relapsed childhood cancers
Disease control Recruiting nowBackground: Acute lymphoblastic leukemia (ALL) is the most common cancer in children. About 90% of children and young adults who are treated for ALL can now be cured. But if the disease comes back, the survival rate drops to less than 50%. Better treatments are needed for ALL re…
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
Can bone marrow stem cells calm lupus kidney flares?
Disease control Recruiting nowThe purpose of this study is to evaluate the safety and efficacy of mesenchymal stem cells (MSCs) obtained from bone marrow for the treatment of adults with active proliferative lupus nephritis. The objective of this study is to evaluate the efficacy of mesenchymal stem cells (MS…
Phase 2 • Sponsor: Red de Terapia Celular • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
New pill could slow Alzheimer's: major trial underway
Disease control OngoingThis AR1001-ADP3-US01 protocol is a double-blind, randomized, placebo-controlled, multi- center, parallel-group comparison pivotal Phase 3 study to evaluate the efficacy and safety of AR1001 for the treatment of participants with early AD.
Phase 3 • Sponsor: AriBio Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New device aims to prevent amputation in patients with no other options
Disease control Recruiting nowA prospective, single-arm, multi-center study designed to gather additional information on the LimFlow System.
Sponsor: LimFlow, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Can a gene therapy instilled in the bladder fight tough bladder cancer?
Disease control OngoingTo evaluate the safety and efficacy of FE 999326 in Japanese subjects with high-grade, BCG unresponsive NMIBC.
Phase 3 • Sponsor: Ferring Pharmaceuticals • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Could a common gout pill and baby aspirin shield diabetic hearts?
Disease control Recruiting nowTo evaluate the efficacy and safety of colchicine and non-enteric coated aspirin, combined or alone, to improve cardiovascular outcomes in high-risk patients with type 2 diabetes.
Phase 3 • Sponsor: Montreal Heart Institute • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Immune-boosting combo aims to wipe out rectal cancer before surgery
Disease control OngoingThis is an open-label, prospective phase II clinical trial to evaluate the therapeutic and prognostic implications of tumor immune microenvironment in the neoadjuvant immunotherapy combined with chemoradiotherapy for patients with rectal cancer. A total of 100 patients will be en…
Phase 2 • Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
New hope for toddlers with brain tumors: tailored therapy aims to boost survival and protect young minds
Disease control Recruiting nowThis is a multi-center, multinational phase 2 trial that aims to explore the use of molecular and clinical risk-directed therapy in treatment of children 0-4.99 years of age with newly diagnosed medulloblastoma.
Phase 2 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New combo therapy aims to extend life in advanced melanoma
Disease control Recruiting nowThe purpose of this study is to evaluate the efficacy and safety of tebentafusp-based regimens, including tebentafusp monotherapy and in combination with anti-PD1 vs investigator choice (including clinical trials of investigational agents, salvage therapy per local standard of ca…
Phase 3 • Sponsor: Immunocore Ltd • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Spinal stimulation trial aims to restore movement in paralyzed patients
Disease control Recruiting nowSpinal Cord Injury (SCI), being a devastating diagnosis, has little to no recovery which leads to a long-standing of debilitating impairment for affected patients. The NNI Neurosurgery team, together with our collaborators, are expanding our recruitment from our pilot trial named…
Sponsor: National Neuroscience Institute • Aim: Disease control
Last updated Jun 27, 2026 08:14 UTC
-
New vaccine-like shot aims to stop breast cancer recurrence in high-risk patients
Disease control Recruiting nowThis is a prospective, randomized, double-blinded, placebo-controlled, multi-center, Phase 3 study of GLSI-100 immunotherapy in HLA-A\*02 positive and HER2/neu positive subjects who are at high risk for disease recurrence and have completed both neoadjuvant and postoperative adju…
Phase 3 • Sponsor: Greenwich LifeSciences, Inc. • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Simple breath test could spot pancreatic cancer sooner
Diagnosis Recruiting nowPatients with early pancreatic cancer often have symptoms that could also be caused by many common benign conditions, or no symptoms at all. Jaundice, weight loss and pain are 'red flag' symptoms of pancreatic cancer that are linked to incurable disease. At the moment only patien…
Sponsor: Imperial College London • Aim: Diagnosis
Last updated Jun 27, 2026 12:34 UTC